Novartis taps Oxford BioMedica in $90M immuno-oncology deal

Novartis ($NVS) has expanded its relationship with the U.K.'s Oxford BioMedica, signing a deal worth up to $90 million that will support the drugmaker's efforts in CAR-T immunotherapies. Under the agreement, Novartis will pay $14 million up front to use Oxford's lentivirus delivery vectors in its work on CTL019, a promising new approach to cancer that involves re-engineering a patient's own T cells. Novartis is also making an equity investment in the company, and the three-year agreement entitles Oxford to some undisclosed royalties on future sales of the treatment. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.